Phreesia, Inc. (NYSE:PHR) General Counsel Allison C. Hoffman Sells 8,426 Shares

Phreesia, Inc. (NYSE:PHR) General Counsel Allison C. Hoffman sold 8,426 shares of Phreesia stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $27.31, for a total value of $230,114.06. Following the transaction, the general counsel now owns 146,126 shares of the company’s stock, valued at $3,990,701.06. The trade was a 5.45 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Phreesia Stock Performance

Shares of PHR stock traded down $0.06 on Wednesday, reaching $27.29. The stock had a trading volume of 389,445 shares, compared to its average volume of 386,096. The stock has a market cap of $1.59 billion, a P/E ratio of -18.56 and a beta of 0.94. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.74 and a current ratio of 1.74. Phreesia, Inc. has a 1 year low of $17.07 and a 1 year high of $29.16. The company has a 50 day simple moving average of $23.77 and a 200 day simple moving average of $22.94.

Phreesia (NYSE:PHR) last released its quarterly earnings results on Monday, December 9th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.04. Phreesia had a negative return on equity of 32.78% and a negative net margin of 20.43%. The business had revenue of $106.80 million during the quarter, compared to the consensus estimate of $106.33 million. During the same period in the previous year, the company posted ($0.58) EPS. The business’s quarterly revenue was up 16.6% compared to the same quarter last year. Equities research analysts expect that Phreesia, Inc. will post -1.1 EPS for the current year.

Analyst Ratings Changes

PHR has been the subject of several analyst reports. JMP Securities restated a “market outperform” rating and set a $30.00 price target on shares of Phreesia in a report on Tuesday, December 10th. Royal Bank of Canada raised shares of Phreesia from a “sector perform” rating to an “outperform” rating and lifted their target price for the stock from $24.00 to $32.00 in a report on Wednesday, January 8th. Needham & Company LLC reiterated a “buy” rating and set a $29.00 price target on shares of Phreesia in a report on Friday, January 10th. KeyCorp boosted their price objective on shares of Phreesia from $28.00 to $30.00 and gave the stock an “overweight” rating in a report on Wednesday, January 8th. Finally, Citigroup upped their price objective on Phreesia from $31.00 to $35.00 and gave the company a “buy” rating in a research report on Friday, January 10th. Twelve analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $31.00.

Hedge Funds Weigh In On Phreesia

Several large investors have recently made changes to their positions in PHR. International Assets Investment Management LLC grew its stake in shares of Phreesia by 2,179.7% in the 3rd quarter. International Assets Investment Management LLC now owns 1,459 shares of the company’s stock worth $33,000 after buying an additional 1,395 shares in the last quarter. Lombard Odier Asset Management USA Corp purchased a new position in Phreesia in the second quarter worth about $202,000. Point72 DIFC Ltd bought a new stake in Phreesia during the second quarter worth approximately $209,000. XTX Topco Ltd purchased a new stake in Phreesia during the third quarter valued at approximately $247,000. Finally, Hsbc Holdings PLC bought a new stake in shares of Phreesia in the 2nd quarter valued at approximately $301,000. 92.10% of the stock is currently owned by hedge funds and other institutional investors.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.